Special Interest Group (SIG)  
on Drug Delivery and Manufacturing (DDM)  
Annual Report 2022

SIG accomplishments during the 2022 calendar year

- Prof. Tetsuya Ozeki participated to the International Pharmaceutical Technology Symposium (IPTS) held online hosted by the Hacettepe University in Turkey and made a lecture and mentioned the SIG DDM on February 21.
- Prof. Tetsuya Ozeki and Prof. Erem Bilensoy, a vice-chair, did the abstract reviewing for the relevant Section of the FIP Seville Congress (before restructuring the Congress)
- Prof. Erem Bilensoy was elected BPS EX Co member in August.
- Prof. Tetsuya Ozeki submitted a Session Proposal to the FIP Congress in Brisbane will be held in September 2023.
- Prof. Hala Fadda, a leader of PFFG, is working on setting up training sessions by compounding experts.
- Pediatric Formulations Focus Group (PFFG) completed their global survey on pediatric oral extemporaneous preparations and practices in May 2022. The survey received a total of 730 responses from all the WHO regions. It confirmed a diversity of practices, but a common global need for freely accessible compounding formulations, stability studies and workforce training. The findings were presented as a poster at the FIP 80th World Congress in Seville.
- PFFG had a zoom meeting on 10th May 2022, 2 pm CET. Global challenges facing pediatric medicines, survey findings and next steps were discussed at the meeting.
- PFFG survey findings were presented at the Board of Pharmaceutical Sciences August 2022 meeting.
- A blog on the ‘The Pediatric Medicines Gap’ written by PFFG Chair, Hala Fadda, was published in FIP-EquityRx Blog. The blog highlighted challenges facing pediatric medicine and the need for the important work undertaken by PFFG.

PFFG survey has been completed and revealed important findings on pediatric oral extemporaneous preparations and practices from all the WHO regions. The findings will be published in a manuscript. The next steps are to develop best strategies and training for oral extemporaneous pediatric compounding through the commitment of PFFG members and engagement with stakeholders. FIP strives to bridge education, science and practice and is therefore in the best position to achieve a global and coordinated effort to address the challenges in pediatric medicines.

SIG goals for the 2023 calendar year (please limit to most relevant 2-3 goals)

- Goal #1: The DDM leadership team engage more effectively with colleagues from various BPP Sections in joint programming activities to underline invaluable relationship between clinical and practical outcomes and scientifically designed drug delivery and manufacturing.
• Goal #2:
To disseminate knowledge and facilitate networking between drug delivery and manufacturing professionals worldwide through webinars, opinion papers or reports

• Goal #3:
PFFG experts will work on developing oral extemporaneous compounding training videos. Hospital and academic pharmacists have committed to doing so by the last quarter of 2022. PFFG will be working with Dalia Bajis, FIP Lead for Provision and Partnerships, to implement the training sessions.
Part B: Input into the 2022 FIP annual report

The FIP annual report covers activities from January to December 2022. The provisional theme of the annual report this year is: “One FIP: United for a healthier world”.

FIP HQ would like to highlight selected SIG activities in its annual report. To facilitate effective integration of your accomplishments in this report, please fill in the box below.

As well as being a promotional tool, an annual report can be used as an internal document to record achievements as well as challenges. You may consider acknowledging substantial contributions of individuals who were instrumental in initiating/completing important tasks relevant to your SIG members. In addition, to recognising and thanking people, an annual report can also serve as a medium to motivate and inspire people to contribute to the goals of the Board of Pharmaceutical Science (BPS).

- In two or three sentences, please highlight one activity that relates to the provisional theme of the annual report “One FIP: United for a healthier world” and describe its impact/outcomes. We greatly appreciate quantitative information if available.

- For the above activity, please provide a positive quote that can be used in the annual report. This quote could be from a person within or external to FIP. It should say something good about FIP/the SIG and why the activity was beneficial. It should reflect well on FIP’s work without being overly promotional.

Quote:
Person’s name, including title (Prof, Dr, Mr, Mrs, Ms):
His or her job/role title:
Email address (so we can contact for a photo if needed):

(For example, in the 2014 annual report (p. 14), the signing of a memorandum of understanding between FIP and Monash University was mentioned. So for the activity (the signing of memorandum), the form would be as follows:

Quote: "Monash University is thrilled to partner with FIP as a means to broaden the reach and scope of the SABER platform to support pharmacy teaching and learning environments through the auspices of FIP."

Person’s name, including title (Prof, Dr, Mr, Mrs, Ms): Prof Bill Charman
His or her job/role title: Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia
Email address (so we can contact for a photo if needed): Bill.Charman@.........)

Last year’s annual report is accessible at https://www.fip.org/publications?publicationCategory=18&publicationYear=&publicationKeyword=, should you wish to refer to it.